- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
PMV Pharmaceuticals Reports Q1 Earnings Beat
The biotech company exceeded analyst estimates by $0.06 per share.
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, reported its first quarter financial results on Friday. The company posted a loss of $0.34 per share, beating the consensus analyst estimate of a $0.40 per share loss by $0.06.
Why it matters
PMV Pharmaceuticals is developing a small molecule therapy that targets a specific p53 mutation found in certain cancer types. The company's ability to exceed earnings expectations could signal progress in its drug development pipeline and provide investors with more confidence in the company's future prospects.
The details
For the quarter, PMV Pharmaceuticals reported a net loss of $0.34 per share, compared to the analyst consensus estimate of a $0.40 per share loss. The company's stock price rose 7.2% on the earnings beat.
- PMV Pharmaceuticals reported its Q1 2026 earnings results on Friday, March 8, 2026.
The players
PMV Pharmaceuticals
A precision oncology company developing small molecule therapies that target p53 mutations in cancer.
The takeaway
PMV Pharmaceuticals' ability to exceed earnings expectations suggests the company is making progress in its efforts to develop novel cancer treatments targeting p53 mutations. This could be an encouraging sign for investors as the company continues to advance its drug pipeline.
